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Objective: Dominant optic atrophy (DOA) is the most common inherited optic neuropathy, with a prevalence of
1:12,000 to 1:25,000. OPA1 mutations are found in 70% of DOA patients, with a significant number remaining
undiagnosed.
Methods: We screened 286 index cases presenting optic atrophy, negative for OPA1 mutations, by targeted next gen-
eration sequencing or whole exome sequencing. Pathogenicity and molecular mechanisms of the identified variants
were studied in yeast and patient-derived fibroblasts.
Results: Twelve cases (4%) were found to carry novel variants in AFG3L2, a gene that has been associated with autoso-
mal dominant spinocerebellar ataxia 28 (SCA28). Half of cases were familial with a dominant inheritance, whereas the
others were sporadic, including de novo mutations. Biallelic mutations were found in 3 probands with severe syndromic
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optic neuropathy, acting as recessive or phenotype-modifier variants. All the DOA-associated AFG3L2 mutations were
clustered in the ATPase domain, whereas SCA28-associated mutations mostly affect the proteolytic domain. The path-
ogenic role of DOA-associated AFG3L2 mutations was confirmed in yeast, unraveling a mechanism distinct from that
of SCA28-associated AFG3L2 mutations. Patients’ fibroblasts showed abnormal OPA1 processing, with accumulation
of the fission-inducing short forms leading to mitochondrial network fragmentation, not observed in SCA28 patients’
cells.
Interpretation: This study demonstrates that mutations in AFG3L2 are a relevant cause of optic neuropathy, broaden-
ing the spectrum of clinical manifestations and genetic mechanisms associated with AFG3L2 mutations, and under-
scores the pivotal role of OPA1 and its processing in the pathogenesis of DOA.
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Introduction
Dominant optic atrophy (DOA) is a frequent optic neu-
ropathy with infantile onset, affecting primarily the
papillomacular bundle, leading to temporal pallor of the
optic disc and loss of central vision with central scotoma,
abnormal color vision, and relentless slow progression.1,2
In 2000, causative heterozygous variants in the
OPA1 gene (NM_130837.2) were reported,3,4 and cur-
rently up to 70% of DOA patients worldwide are esti-
mated to carry an OPA1 mutation.5 DOA prevalence may
range from 1:12,000 to 1:25,000.2,5,6 OPA1 is a
multifunctional mitochondrial protein, expressed in
8 isoforms from alternative splicing of 3 exons (4, 4b, and
5b), further processed from long (L) to short (S) forms,
due to 2 cleavage sites for the mitochondrial proteases
YME1L (i-AAA) and OMA1.7 The main function of
OPA1 L and S forms is to drive and regulate fusion and
fission of the inner mitochondrial membrane (IMM),
respectively,8 finely sensing the metabolic needs of the
cells.9 In regulating the dynamics of the IMM, OPA1 cru-
cially shapes the structure of mitochondrial cristae and
contributes the respiratory chain supercomplexes assem-
bly.10 Thus, OPA1 mutations may result in defective oxi-
dative phosphorylation in DOA patients.11,12
Most DOA-related OPA1 mutations are predicted to
lead to haploinsufficiency, whereas missense mutations are
less frequent.13 Some families are characterized by syn-
dromic association of DOA with sensorineural deafness
and chronic progressive external ophthalmoplegia, defined
as DOA “plus.”14–16 Notably, compound heterozygous
OPA1 mutations have been described in a few cases man-
ifesting complex neurological involvement in addition to
optic atrophy.13,17,18
About 30% of DOA patients, however, do not carry
OPA1 mutations. Heterozygous mutations in a second
gene, associated with DOA and cataracts and/or deafness,
affect the OPA3 gene,19,20 known for the recessive Costeff
syndrome (Online Mendelian Inheritance in Man data-
base [OMIM] #258501). A third gene, carrying heterozy-
gous mutations associated with DOA and deafness, is
WFS1,21 known for the recessive Wolfram syndrome
(OMIM #222300), and a fourth gene associated with
DOA is DNM1L (OPA5) encoding DRP1, a crucial pro-
tein involved in mitochondrial fission.22
More recently, heterozygous mutations in the
AFG3L2 gene were described in 3 unrelated patients with
nonsyndromic23,24 and syndromic25 optic atrophy.
AFG3L2 encodes 1 of the 2 subunits—the other being
SPG7/paraplegin—of the mitochondrial matrix AAA meta-
lloprotease (m-AAA), an adenosine triphosphate (ATP)-
dependent proteolytic complex located in the IMM, where
it carries out protein quality control and participates in the
processing and maturation of some mitochondrial
proteins.26–28 Heterozygous mutations in AFG3L2 are
known to cause autosomal dominant spinocerebellar ataxia
28 (SCA28),29 whereas, rarely, homozygous AFG3L2
mutations have been associated with a complex autosomal
recessive spastic ataxia syndrome (SPAX5).30
Here, we report the identification of novel heterozy-
gous mutations in AFG3L2 in OPA1-negative DOA fami-
lies or sporadic cases, presenting clinical features nearly
indistinguishable from OPA1-related DOA. A few patients
exhibited additional neurological symptoms, carrying com-
pound heterozygous AFG3L2 variants, suggestive of a
recessive pattern of inheritance. To validate pathogenicity
and elucidate the molecular basis of these mutations, we
performed yeast and cellular studies, ultimately demon-
strating altered OPA1 processing leading to excessive
mitochondrial fragmentation as final pathogenic mecha-
nism also in AFG3L2-associated optic atrophy.
Subjects and Methods
Genetic Screening
A cohort of subjects with isolated or syndromic optic neuropathy,
negative for OPA1 mutations, were investigated by different genetic
screenings at 3 referral centers (Bologna, Milan, and Tübingen). All
the procedures involving human subjects were approved by the insti-
tutional review boards. Each individual providing a biological sample
signed informed consent. Genomic DNA was extracted from
peripheral-blood lymphocytes using standard procedures.
Patients were screened by different next generation
sequencing (NGS) approaches. Eighty-one index cases were
2 Volume 00, No. 0
ANNALS of Neurology
investigated by a panel including 35 genes (list available upon
request) associated with genetic forms of optic atrophy. The
amplicon-based NGS library (TruSeq Custom Amplicon;
Illumina, San Diego, CA) was sequenced on Illumina MiSeq.
Independently, 5 subjects (2 index cases and 3 additional sub-
jects) from 2 families (Families 5 and 6) were analyzed by whole
exome sequencing (WES; Agilent SureSelect Human All Exon
50 M; Agilent Technologies, Santa Clara, CA) on Illumina
HiSeq. An additional 203 index cases were screened using a
panel of genes associated with mitochondrial disorders, including
optic atrophy (list available upon request). The capture-based
NGS library (Nextera Rapid Capture Custom Kit, Illumina) was
sequenced on Illumina MiSeq.
For bioinformatic analysis, reads were aligned to the
human genome (hg19) and the identified variants were anno-
tated (ANNOVAR) and filtered, focusing on rare variants
(≤0.5% in public databases) causing potentially damaging
changes (Combined Annotation Dependent Depletion,
PolyPhen-2, DANN). Variant confirmation and segregation
analysis were performed by Sanger sequencing.
Case Reports
Pedigrees are shown in Figure 1, and clinical features are summa-
rized in the Table and Supplementary Table S1.
Family 1. The proband (I-1) is a 74-year-old male pre-
senting slowly progressive visual loss manifesting with
bilateral temporal pallor of the optic discs in his 50s. Lac-
tic acid, electromyography, and brain magnetic resonance
imaging (MRI) were normal, except for mineral deposits
at basal ganglia. Audiometry revealed bilateral sensorineu-
ral deafness. Visual evoked potentials documented bilateral
delayed latencies and reduced amplitude of cortical
responses. Three other relatives were similarly affected.
Family 2. This is a large family, with several affected
members. The proband (IV-1), a 60-year-old male, was
diagnosed at 36 years with optic atrophy and glaucoma.
His visual function progressively worsened. Two of the
3 proband’s offspring (V-2, V-3) were mildly affected,
whereas 1 (V-1) was clinically unaffected but with a mild
temporal thinning of the retinal nerve fiber layer (RNFL).
Family 3. This sporadic case is a 15-year-old child who
had been complaining of visual disturbances since child-
hood (6 years). Brain MRI showed atrophy of the optic
nerves, chiasm, and optic tracts. He had intellectual dis-
ability, with more profound nonverbal (intelligence quo-
tient [IQ] = 36) than verbal (IQ = 62) performance
defect.
Family 4. The proband (III-1) is a 24-year-old male pre-
senting visual disturbances since childhood (3 years).
Lactic acid was normal. His father (II-1) presented both
optic atrophy and bilateral sensorineural deafness.
Family 5. The proband (II-5) is a 74-year-old male. Since
childhood, he had poor vision. At 60 years, he manifested
slowly progressive ataxic–spastic gait and a mild hearing
defect. Brain MRI displayed cerebellar atrophy, mild cere-
bral atrophy, and severe optic atrophy. Electromyography
showed axonal neuropathy. At last examination, he
showed blindness, with severe ophthalmoparesis and nys-
tagmus, moderate hearing loss, mild speech impairment,
generalized hypotonia without weakness, ataxic–spastic
gait, and global hyperreflexia. Muscle respiratory chain
activities were normal. The proband’s father (I-1) and
brother (II-1) were referred to have optic atrophy and
hearing loss. The 47-year-old proband’s son (III-5) had
nystagmus and optic atrophy since early childhood
(3 years). At last examination, hearing was normal and
there were no signs of neurological involvement. He had
severe visual loss with complete color blindness, very poor
visual acuity (0.1), and pale optic discs. Optical coherence
tomography (OCT) examination showed bilateral severely
reduced RNFL thickness.
Family 6. Three individuals were affected with optic atro-
phy. The mother (I-2) first noticed visual reduction at
8 years of age, which remained mild until the current age
of 65 years. At 55 years old, she first noticed a non-
progressive cervical dystonia, still responsive to botulinum
toxin treatment 10 years later. Currently, she remains neg-
ative for signs of cerebellar ataxia, spasticity, myoclonus,
or chorea. Her son (II-2) noticed reduced visual acuity
since 4 years of age, which has been mildly progressive,
with difficulties to read small letters at the current age of
40 years. Currently, he has no signs of cerebellar ataxia,
spasticity, or other movement disorder. The daughter
(II-1) showed optic atrophy since 2 years of age, which
progressed after age 15 years, leading to bilateral blindness.
She also had childhood myoclonus of the extremities since
8 years of age, and a progressive spastic–ataxic gait disor-
der since 15 years of age. At 35 years old, she showed
blindness, a mild-to-moderate cerebellar ataxia (Scale for
the Assessment and Rating of Ataxia [SARA] score = 7
points), paraspasticity, myoclonus of the extremities, and
chorea of the hands. Ataxia progressed, and SARA score
was 13.5 points at 43 years. The father (I-1) was subjec-
tively asymptomatic. However, at 64 years old, he showed
signs of ataxia, with a borderline SARA score of 4 points
(cutoff > 3 points). No other neurological abnormalities
were observed, and ophthalmological examination and
brain MRI were negative.
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Family 7. A sporadic patient, a 39-year-old woman, presented
visual loss starting 2 years previously. Optic nerves were
reported normal on brain MRI. The neurological examination
was normal except for a mild reduction of deep tendon reflexes.
Family 8. A sporadic patient, a 19-year-old male, pres-
ented visual loss since infancy. Brain MRI showed optic
nerve hypotrophy. He showed diffuse optic disc pallor
and size reduction of retinal arterial vessels. He had pres-
ented congenital nystagmus, spontaneously resolved at
10 years. His brother had normal vision. The father had
no visual or neurological disturbances, but he did not
undergo ophthalmological examination.
Family 9. A sporadic 11-year-old girl who had showed optic
atrophy at age 9 years. Neurological examination was normal
as well as brain computed tomography scan. OCT was nor-
mal in her parents and brother.
Family 10. The proband (III-1) is a 19-year-old girl. Fam-
ily history was positive for early onset optic atrophy (II-1,
II-3, and I-2). She had presented psychomotor delay.
Optic atrophy was detected at 2 years. During childhood,
she showed neurological signs of motor disturbance. At
15 years, brain MRI showed diffuse mild cerebral atrophy.
At 18 years, neurological evaluation showed tetraparesis,
bradykinesia, dystonia, and cognitive involvement.
Family 11. A sporadic patient, an 18-year-old male, presented
at 4 years with walking difficulties and gait ataxia. He then
developed involuntary hyperkinetic movements of the upper
limbs and a dystonic posture. Visual deficit became evident at
9 years of age, and optic atrophy was detected. He now pre-
sents ataxia, dysmetria, dysarthria, and dystonia. At 6 years,
MRI disclosed T2-hyperintensity of the putamen, pallidus,
and substantia nigra; MRI follow-up showed caudate nuclei
(11 years) and subthalamus (14 years) involvement. Ophthal-
mological evaluation was normal in the father (I-1), and the
FIGURE 1: Pedigree of the 12 optic atrophy families with segregation of the identified AFG3L2 variants. Black symbols indicate
patients with optic neuropathy; gray symbols indicate subjects with subclinical phenotype. Arrows indicate family index cases.
Asterisks indicate individuals manifesting optic atrophy along with adjunctive neurological findings (see details in the Table).
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TABLE. Genetic and Neuro-Ophthalmological Findings
Family Identifier
Age,
yr
AFG3L2
Mutation
VA
Reduction
Abnormal
Color
Vision
FO
Pallor
OCT
Neurological Findings
(decreased
RNFL
thickness)
F1 I-1 74 c.1385C > T p.A462V + + + + —
II-4 49 − + + + —
II-7 45 + + + + —
III-3 29 + + + + —
F2 IV-1 60 c.1385C > T p.A462V + + + + —
V-1 33 − − − + —
V-2 32 + + + + —
V-3 25 + + + + —
F3 II-3 15 c.1394G > A p.R465K + + + + Mild intellectual
disability
F4 II-1 63 c.1220A > G p.D407G + + + + Sensorineural deafness
III-1 24 + + + + Heterotopic cortical
nodule adjacent to
lateral left ventricle
F5 II-5 74 c.1541C > T p.P514L + + + + Spastic paraparesis
III-5 47 + + + + —
F6 I-1 64 c.1858C > A p.Q620K − − − − Very mild ataxia,
subjectively unnoticed
I-2 65 c.1385C > T p.A462V − + + + Cervical dystonia
II-1 36 c.1385C > T
c.1858C > A
p.A462V
p.Q620K
+ + + + Ataxia, spasticity,
myoclonus Distal
chorea,
II-2 40 c.1385C > T p.A462V + + + + depression
F7 II-3 39 c.1289C > T p.T430I − − + + Mild reduction of deep
tendon reflexes
F8 II-1 19 c.1036C > T p.L346F + + + + Congenital nystagmus
(spontaneously
resolved)
F9 II-1 11 c.1130 T > C p.F377S + + + + —
F10 II-1 53 c.1064C > T p.T355M + + + + —
III-1 19 ne ne + ne Hyperkinetic
movements, cerebellar
signs, dystonia
F11 I-1 57 c.1901_1902delCT p.S634* − − − − —
I-2 58 c.916A > G p.K306E − − − − —
II-1 18 c.1901_1902delCT
c.916A > G
p.S634*
p.K306E
+ + + + Cerebellar signs and
dystonia
F12 I-1 72 c.1814A > G p.Y605C − − − − —
I-2 71 c.2375dupG p.E793* − − + + —
II-1 42 c.1814A > G
c.2375dupG
p.Y605C
p.E793*
+ + + + —
Variants refer to SeqRef NM_006796.3.
FO = fundus oculi; ne = not evaluable; OCT = optical coherence tomography; RNFL = retinal nerve fiber layer; VA = visual acuity.
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mother (I-2) showed only a slight maculopathy unrelated to
the son’s pathology. Both parents were neurologically normal.
Family 12. This 42-year-old male was diagnosed with
optic atrophy when he was 4 years old. Visual function
remained stable. At 17 years, brain MRI and neurological
examination were normal. The mother (I-2) was clinically
normal, but OCT demonstrated a reduction of RNFL in
the temporal quadrants. Except for amblyopia in the left
eye, the father (I-1) was clinically asymptomatic, and the
ophthalmologic examination confirmed a normal RNFL.
Yeast Studies
Five AFG3L2 variants (NM_006796.3) identified in patients
(p.D407G, p.A462V, p.R465K, p.P514L, p.Q620K) were func-
tionally studied in a yeast model, as previously described.25,29 Frag-
ments spanning the selected variants were generated by Invitrogen
FIGURE 2: Ophthalmologic findings. Ophthalmologic features in 2 patients: a mild case (F2 IV-1; A, C, and E) and a severe case
(F3 II-3; B, D, and F). For each case, fundus oculi (A, B), Humphrey visual fields 30–2 (C, D), and retinal nerve fiber layer (RNFL)
thickness measurements on optical coherence tomography (E, F) are reported. The mild case displays only a temporal pallor at
fundus oculi, which congruently corresponds to central scotoma, and a selective temporal loss of RNFL thickness. The severe
case presents with generalized pallor of the optic disk, widespread loss of sensitivity at visual field, and global loss of RNFL
thickness. I,INF = inferior; L = left; N,NAS = nasal; OD = "Oculus Dexter" or right eye; OS = "Oculus Sinister" or left eye; R =
right; S,SUP = superior; T,TMP = temporal.
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(Carlsbad, CA) GeneArt Gene Synthesis and cloned into the yeast
construct pYC6/CT-ADH1-AFG3L2-V5.29 All strains used in this
study were obtained transforming the double-knockout yeast strain
(yta10Δyta12Δ) derived from strain W303 with AFG3L2
(NM_006796.3) and paraplegin (SPG7, NM_003119.3) expres-
sion plasmids.25,29
Fibroblast Cell Culture
Skin fibroblasts were derived from 2 unrelated healthy donors
and 6 optic atrophy patients from 3 families. Fibroblasts were
grown in Dulbecco modified Eagle medium (DMEM) medium
supplemented with 10% fetal bovine serum, 2mM L-glutamine,
and antibiotics. For the experiments, we used DMEM glucose
medium or DMEM glucose-free medium containing 5mM
galactose and 5mM pyruvate.31
Immunoblot Analysis
Immunoblot analysis of AFG3L2, Ccp1, MrpL32, paraplegin,
and OPA1, using actin, HSP60, or MTPα as loading controls,
was performed on yeast cells or patient-derived fibroblasts as pre-
viously described.29
Mitochondrial Network Morphology
The mitochondrial fluorescent dye MitoTracker Red-CMXRos
(Invitrogen) was used to visualize the mitochondrial network in
live cells, and circularity of mitochondria was calculated using
the image processing package ImageJ (Fiji).32
Alternatively, mitochondrial network was labeled with the
anti-TOM20 antibody and cells were classified by blind test into
3 categories as follows: filamentous, intermediate, and fragmen-
ted mitochondria.31
Oxygen Consumption Studies
The oxygen consumption rate (OCR) was measured using XF
24-well or XF 96-well cell culture microplates (Seahorse Biosci-
ence, Billerica, MA) as previously described.31,33
Statistical Analyses
The data were analyzed by 1-way analysis of variance with
Dunnett multiple comparisons test and unpaired 2-tailed t test,
using Prism version 6.07 (GraphPad Software, San Diego, CA).
Differences between groups were considered to be significant
at p < 0.05.
Data Availability
Supporting data for this study are available from the
corresponding authors upon request.
Results
Genetic Analysis Reveals Mutations in AFG3L2
We screened a total of 286 index cases presenting optic
atrophy and negative for OPA1 mutations. We identified
12 probands harboring AFG3L2 variants: 10 of 284 by
disease-related (optic atrophy and mitochondrial disorders)
multigene panels and 2 by WES. Overall, these results indi-
cate a frequency of ~4% in our OPA1-negative optic atrophy
cohort. Six of 12 index cases are familial cases with an auto-
somal dominant pattern of inheritance (F1, F2, F4, F5, F6,
and F10), whereas six (F3, F7, F8, F9, F11, and F12) are
sporadic. From the 12 families, a total of 24 affected subjects
with AFG3L2 variants were identified (see Fig 1). A
FIGURE 3: Mutation distribution on AFG3L2 protein. AFG3L2 (NM_006796.3) pathogenic variants associated with optic atrophy
(red), spinocerebellar ataxia 28 (SCA28; black), and spastic ataxia syndrome 5 (SPAX5; blue) phenotypes. Details and references
are reported in Supplementary Table 2. Variants reported in this study are in bold. Biallelic variants are underlined. The
distribution of pathogenic variants associated with isolated optic atrophy, which are predominantly located in the ATPase
domain, is distinct from those associated with SCA28 and SPAX5, which are mainly located in the proteolytic domain.
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summary of neuro-ophthalmological and neurological pheno-
type is reported in the Table and Supplementary Table S1,
and the neuro-ophthalmological features in 2 patients from
2 families (F2 IV-1 and F3 II-3) are depicted as an example
in Figure 2.
Nine families (F1–F5 and F7–F10) harbored a single
heterozygous missense variant, with an autosomal dominant
pattern of inheritance in 5 cases (p.A462V, F1 and F2;
p.D407G, F4; p.P514L, F5; p.T355M, F10) and a sporadic
presentation in the remaining. Among these, 2 variants were
de novo (p.R465K, F3 and p.F377S, F9), 1 was inherited from
an asymptomatic father (p.L346F, F8), suggesting reduced
penetrance or a subclinical phenotype, and 1 (p.T430I, F7)
was detected in the only affected member of the family, with
no genetic data available from the relatives.
In 2 families, the index case carried biallelic variants,
with a missense change in compound heterozygosity with
a frameshift mutation (p.K306E + p.S634* in F11 and
p.Y605C + p.E793* in F12). In both cases, the disease
clinically manifested in the compound heterozygotes only,
which would suggest a recessive inheritance pattern.
Finally, Family 6 exhibited a more complex geno-
type, with 2 heterozygous AFG3L2 missense variants,
p.A462V and p.Q620K. Interestingly, individuals harbor-
ing p.A462V only (F6 I-2 and II-2) exhibited a pure optic
atrophy phenotype (with only mild late onset cervical dys-
tonia in F6 I-2), whereas patient F6 II-1, carrying both
p.A462V and p.Q620K, had a more complex phenotype
characterized by optic atrophy, severe childhood onset
ataxia, spasticity, and generalized dystonia. The father
FIGURE 4: Studies in yeast cells expressing mutant human AFG3L2. Respiratory phenotype of yta10Δyta12Δ yeast cells
expressing normal and mutant human AFG3L2 is shown. Serial dilutions of normalized yeast cultures were spotted on YEP plates
containing 2% glucose (YPD) or 2% glycerol (YPG) and incubated at 28C for 3 days. Respiratory competence was deduced by
the ability to grow on 2% glycerol (YPG). (A) Respiratory phenotype of K699 (wild-type [WT] yeast strain) and yta10Δyta12Δ cells
expressing either normal (WT) AFG3L2 or AFG3L2 carrying the mutations indicated. (B) Respiratory phenotype of K699 and
yta10Δyta12Δ cells coexpressing either normal or mutant human AFG3L2 with human paraplegin. Dislocase (ATPase) and
proteolytic activity of normal and mutant human AFG3L2 in yeast is shown. (C, D) Fluorescence immunoblot analysis of Ccp1 and
MrpL32 precursor (p) and mature (m) forms in yeast cells expressing either normal (WT) or mutant human AFG3L2 alone (C) and
coexpressed with paraplegin (D). Dislocase (ATPase) and proteolytic competence is assessed by precursor accumulation of Ccp1
and MrpL32, respectively. The slightly larger size of AFG3L2 observed in lanes 3–6 of C and D indicates defective autocatalytic
processing25,48 due to the proteolytic defect of mutants p.D407G, p.A462V, p.R465K, and p.P514L. β-Actin was used as loading
control in C and D. YEP plates = yeast growth medium composed of Yeast Extract and bacto-Peptone.
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(F6 I-1), carrying p.Q620K, was subjectively asymptom-
atic, showing only borderline signs of mild ataxia at neu-
rological examination and no clinical signs of optic
atrophy at the age of 64 years.
All the identified variants are not reported in the
gnomAD database (https://gnomad.broadinstitute.org). All
dominant variants associated with pure optic atrophy (8/11)
affect amino acid residues, evolutionarily conserved from bac-
teria to humans (not shown), in the AAA domain (ATPase
domain; Fig 3).
Yeast Model Confirms the Pathogenicity of the
Identified AFG3L2 Variants
The functional effect of 5 representative missense substitu-
tions identified in our cohort of patients was assessed
using the yeast model previously described.29 In particular,
we functionally tested 4 variants affecting the ATPase
domain and associated with optic atrophy phenotype
(p.D407G, p.A462V, p.R465K, p.P514L) and the variant
p.Q620K that affects the proteolytic domain and is associ-
ated with a complex phenotype when in compound het-
erozygosity with p.A462V (F6 II-1).
Human AFG3L2 protein carrying these variants was
expressed in a yeast strain defective for YTA10 and YTA12,
the yeast orthologs of human AFG3L2 and paraplegin,
respectively (yta10Δyta12Δ). Complementation studies with
wild-type AFG3L2 and the 5 variants showed that the respi-
ratory defect (oxidative phosphorylation [OXPHOS] pheno-
type) of yta10Δyta12Δ was rescued by wild-type AFG3L2,
but not by mutant AFG3L2, demonstrating a deleterious
effect of all these variants on the function of AFG3L2 homo-
complex (Fig 4A). Moreover, to evaluate the variant effect
on the AFG3L2/paraplegin heterocomplex, wild-type and
mutant AFG3L2 were coexpressed along with paraplegin
(see Fig 4B). Strains carrying p.D407G, p.A462V, p.R465K,
and p.P514L AFG3L2 variants along with paraplegin
exhibited an OXPHOS phenotype. Interestingly, paraplegin
coexpression in the strain carrying the p.Q620K variant
completely rescued the respiratory defect.
Furthermore, to evaluate the variant effect on the
proteolytic and dislocase activity of the m-AAA complexes,
we tested the processing of 2 known substrates of yeast
m-AAA, the ribosomal subunit MrpL3227 and the reactive
oxygen species (ROS) scavenger protein Ccp1.26 In
FIGURE 5: AFG3L2 and OPA1 analysis in patients’ fibroblasts. Protein expression in fibroblasts derived from 6 probands from
3 families (F2 IV-1; F5 II-5, III-5; F6 I-2, II-1, II-2) and controls are displayed; for each sample, family and subject identifier as well
as the AFG3L2 mutation are indicated. (A) Western blot of AFG3L2 expression levels. (B) Actin was used as a loading control.
(C) Western blot of OPA1 expression levels, with indication of long (L1, L2) and short (S1, S2, S3) bands; MTPα was used as a
loading control. (D) HPS60 was used as mitochondrial mass indicator. (E-F) Densitometric analysis of C shows a reduction of
OPA1long/OPA1short ratio in all fibroblasts carrying AFG3L2 mutations (E) with no change in the total amount of OPA1 (F). Data,
normalized to the control cells, are mean  standard deviation of 3 independent experiments. Statistical analysis was performed
by 1-way analysis of variance with Dunnett multiple comparisons test. Asterisks indicate statistical significance (*adjusted
p < 0.05, **adjusted p < 0.001).
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particular, the conversion of MrpL32 from precursor to
mature form is an indicator of the overall proteolytic compe-
tence, whereas the maturation of Ccp1 indicates the ATP-
dependent capacity of m-AAA complex to dislocate proteins
from the inner mitochondrial membrane (dislocase activ-
ity).34,35 In strains carrying the p.D407G, p.A462V, p.
R465K, and p.P514L AFG3L2 variants, both Ccp1 and
MrpL32 accumulate as precursor, suggesting that these vari-
ants abolished both the ATPase-dependent dislocase activity
and the proteolytic competence (see Fig 4C, lanes 3–6). By
contrast, p.Q620K AFG3L2 is able to normally process both
Ccp1 and MrpL32 (compare lanes 7 and 2 in Fig 4C),
(Figure legend continues on next page.)
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indicating that this AFG3L2 mutant substantially maintains
both proteolytic and ATPase (dislocase) activity.
In yeast cells expressing m-AAA heterocomplexes
constituted by wild-type or mutant AFG3L2 and para-
plegin (see Fig 4D), the processing pattern of Ccp1 and
MrpL32 is the same as in the presence of the homo-
complex (see Fig 4C).
Taken together, these results demonstrate that all
the tested variants affect AFG3L2 function, confirming
their pathogenic role. Notably, the variants located in
the ATPase domain (p.D407G, p.A462V, p.R465K, and
p.P514L) affect also the heterocomplex function and show
a defect in both proteolytic and dislocase activity. By con-
trast, the p.Q620K variant causes a respiratory defect (see
Fig 4A) but shows no alteration in processing these sub-
strates and is rescued by paraplegin coexpression, thus rep-
resenting a paraplegin-responsive mutation as the majority
of AFG3L2 mutations causing SCA28 previously tested.29
Cell Studies Demonstrate Alteration of OPA1
Processing
To evaluate the effect of the missense AFG3L2 mutations
in a human context, we analyzed skin fibroblasts from
6 patients from 3 families (F2 IV-1; F5 II-5, III-5; F6 I-2,
II-1, II-2). Immunoblot analysis did not show any signifi-
cant reduction in the expression level of AFG3L2 protein
in mutant fibroblasts compared to controls (Fig 5A, B, D).
We also assessed OPA1 expression; although the total
amount of OPA1 protein was similar in patients and con-
trol cells (see Figure 5C-F), we observed a significant reduc-
tion of L form (L1 + L2) to S form (S1 + S2 + S3) ratio
(see Fig 5C–E), suggesting an increased proteolytic cleavage
of long forms of OPA1 and accumulation of short forms.
Altered Mitochondrial Network in Fibroblasts
with AFG3L2 Mutations
Because balance of short and long OPA1 forms is required
for mitochondrial fusion activity in mammals,36 we investi-
gated the fibroblast mitochondrial network by morphometric
analyses in fibroblasts from 5 affected members from 2 fami-
lies (F5 II-5, III-5; F6 I-2, II-1, II-2). Fibroblasts were grown
in galactose medium for 48 hours, stained with fluorescent
dye. Overall, we observed a significant fragmentation of
mitochondrial network in patients’ fibroblasts, as demon-
strated by higher circularity values compared to controls,
with the most altered network in the subject harboring
biallelic AFG3L2 mutations (F6 II-1; Fig 6A–I).
Mitochondrial fragmentation was also observed in
fibroblasts from a Family 2 patient (IV-1; see Fig 6J–L).
Fibroblasts were grown in DMEM glucose or galactose
medium, stained with a mitochondrial marker (TOM20),
fixed, and then scored into 3 categories (filamentous,
intermediate, fragmented). In glucose medium, both con-
trol and patient’s fibroblasts exhibited a similar percentage
of cells with filamentous and intermediate mitochondria
(data not shown). After 48-hour incubation in galactose
medium, AFG3L2 mutant fibroblasts significantly
increased the percentage of intermediate and fragmented
mitochondria (see Fig 6J–L), as observed in fibroblasts
from patients with OPA1 mutations.11,31 By contrast,
mitochondrial morphology in control fibroblasts was simi-
lar in both growth conditions.
Despite the alterations in mitochondrial network,
measurement of OCR levels (F2 IV-1; F5 II-5, III-5; F6
I-2, II-1, II-2) did not reveal reduction of energetic com-
petence of AFG3L2 mutant fibroblasts compared to con-
trols (see Fig 6M, N). Congruently, assessment of
OXPHOS complex activity was within normal range in
muscle biopsies available from 2 patients, F5 II-5 and F11
II-1 (see Fig 6O).
Discussion
This study demonstrates that heterozygous mutations in
AFG3L2 are a relevant cause of optic atrophy in
OPA1-negative DOA, impacting about 4% in our cohort.
Remarkably, the large majority of these mutations affected
the AAA (ATPase) domain, in contrast to the AFG3L2
FIGURE 6: Morphology of mitochondrial network in patients’ fibroblasts. (A–H, J, K) Analysis of mitochondrial morphology in live
cells with the mitochondrial dye MitoTracker Red-CMXRos (A–H) and in fixed cells labeled with the anti-Tom-20 (J-K), by
fluorescence microscopy in control (n = 4) and patient (n = 6) fibroblasts, incubated in Dulbecco modified Eagle medium–
galactose for 48 hours. Representatives images are shown for each cell line: controls (A, B, C); Family 5 II-5 (D) and III-5 (E);
Family 6 I-2 (F), II-1 (G), and II-2 (H); control (J); and Family 2 IV-1 (K). Scale bars = 25μm. Analysis of the mitochondrial shape
factors (circularity) are reported in the graphs. (I) Data (mean  standard deviation) are presented as percentage compared to
controls. (L) Quantitative analysis of mitochondrial morphology classified as fragmented (dark gray), intermediate (light gray),
and filamentous (black). Patients’ fibroblasts display a fragmented mitochondrial network. (M, N) Mitochondrial bioenergetics
analysis. Oxygen consumption rate was measured by Seahorse in basal condition and after injection of 1μM oligomycin, 1μM
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone, 1μM rotenone, and/or 1μM antimycin A. The oxygen consumption rate
values (pmolO2−1min−1) were normalized either for protein content, as determined by the sulforhodamine B assay,31 or for cells
number, as determined by CyQuant (Invitrogen). The analysis was carried out on fibroblasts from 2 controls and 6 patients
(Family 2: IV-1; Family 5: II-5, F5 III-5; Family 6: I-2, II-1, II-2) expressed as maximum respiration rate (MRR; M) and respiratory
control ratio (RCR; N). (O) Activities of mitochondrial respiratory chain complexes in muscle biopsies from Patients F5 II-5 and
F11 II-1. Dashed lines indicate range of controls activity. Statistical analysis was performed by unpaired 2-tailed t test. Asterisks
indicate statistical significance (*p < 0.01).
11
Caporali et al: AFG3L2 and Optic Neuropathy
mutations associated with SCA28 and SPAX5 phenotypes,
which are clustered in the proteolytic domain (see Fig 3). In
some peculiar families, probands carried biallelic AFG3L2
mutations inherited from heterozygous parents, leading to
more complex phenotypes. In these cases, optic atrophy
remains the major feature, but adjunctive central nervous sys-
tem involvement of variable severity was observed, including
the extreme case of a Leigh-like phenotype (F11 II-1).
Modeling 5 AFG3L2 mutations in yeast clearly defined their
pathogenic potential. Moreover, investigation of patient-
derived fibroblasts revealed an altered processing of long to
short OPA1 isoforms, with a slight excess of short forms.
This was consistently reflected in the hyperfragmented mito-
chondrial network, when cells were forced to use OXPHOS
in galactose medium, a condition that limits the availability
of ATP production by glycolysis. Ultimately, our findings
suggest that the unbalanced processing of OPA1 consequent
to AFG3L2 dysfunction possibly leads to the optic atrophy
phenotype, thus providing the first insights into the mecha-
nistic basis underlying this phenotypic cluster. The defective
mitochondrial dynamics3,4 fits well with the general para-
digm of the pathogenic mechanism for mitochondrial optic
neuropathies.
The current study expands on previous case reports on
single patients with optic atrophy associated with mutations
in the 2 components, AFG3L2 and SPG7/paraplegin, of m-
AAA protease: 2 patients with a heterozygous AFG3L2
mutation (p.R468C) in the ATPase domain associated with
nonsyndromic optic atrophy23,24; 1 patient with early onset
optic atrophy, spastic ataxia, and L-dopa–responsive parkin-
sonism, heterozygous for both the AFG3L2 p.R468C muta-
tion and an intragenic deletion in the SPG7 gene25; and a
single family with DOA associated with SPG7 heterozygous
mutation.37 Furthermore, a homozygous mutation in the
YME1L1 gene, encoding 1 of the 2 proteases known to pro-
cess OPA1, was found to cause infantile onset developmental
delay, muscle weakness, ataxia, and optic atrophy.38 Thus,
the genetic landscape of optic atrophy, including syndromic
(“plus”) phenotypes, is expanded to include a new class, the
AAA proteases involved in mitochondrial protein quality
control. Notably, dominant, recessive, biallelic, or digenic
inheritance patterns may occur.
SPG7 and AFG3L2 encode the cognate subunits of
the mitochondrial m-AAA protease complex, which carries
out protein quality control by degrading nonassembled or
damaged proteins of the IMM. It has been proposed that
m-AAA loss may lead to overaccumulation of de novo syn-
thesized proteins in the IMM, which in turn would cause
mitochondrial membrane potential dissipation and stress-
activation of the OMA1 metalloprotease that processes the
long OPA1 isoforms to the shortest ones.40 An abnormal
processing pattern of OPA1 has been observed in cells
from the patient with concurrent AFG3L2 and SPG7
mutations associated with early onset optic atrophy and a
complex neurological phenotype.25 Our current results in
patient-derived fibroblasts carrying distinct AFG3L2 muta-
tions provide conclusive evidence that m-AAA protease
activity impinges on OPA1 processing, which ultimately
affects mitochondrial dynamics, thus presenting a com-
mon hub and key function for optic nerve maintenance.
Similarly, mice lacking Afg3l2 exhibit fragmented
mitochondrial network, leading to neurodegeneration.41
This was proposed to be due to impaired metabolism of
OPA1, which mediates mitochondrial fusion.42 Evidence
of a pathologic effect of mutant SPG7 on optic nerve has
been also provided in Spg7-deficient mice, documenting
ultrastructural mitochondrial abnormalities and hyper-
fragmentation of the mitochondrial network,43 features
resembling those seen in postmortem tissues from patients
with DOA or Leber hereditary optic neuropathy.1 Inter-
estingly, patients with biallelic SPG7 mutations showed
increased mitochondrial biogenesis with hyperfused
mitochondria,44 as did the recently described patients with
DNM1L mutation.22 This latter study demonstrates that
optic neuropathy may result from impairment of either
fusion or fission, both leading to opposite profound dys-
function of mitochondrial dynamics.45 The impairment of
the finely tuned mitodynamic processes affects mitochon-
drial morphology, bioenergetic efficiency, and ultimately
mitochondrial biogenesis and maintenance.46
Remarkably, all the dominant AFG3L2 mutations asso-
ciated with optic atrophy affect the ATPase domain, in sharp
contrast with those associated with SCA28 or SPAX5, which
affect the proteolytic domain (see Fig 3, Supplementary
Table 2).47 Notably, the SPG7mutation p.D411A reported to
segregate with isolated DOA is also located in the AAA domain
and is predicted to interfere with ATP binding/hydrolysis, ulti-
mately impairing proteolytic activity.37 Recently, using an
atomic model of the human AFG3L2 homohexamericm-AAA
protease trapped in the act of processing substrate, it has been
demonstrated that clustering of AFG3L2 disease-associated
mutations into distinct regions in the structure correlates with
distinct effects on the mechanism of AFG3L2.47 Consistent
with this model, functional analysis in yeast (see Fig 4) demon-
strated that DOA-associated AFG3L2 mutations (p.D407G,
p.A462V, p.R465K, and p.P514L) drastically impair both the
ATPase-dependent dislocase activity, essential for the
processing of membrane proteins, and the proteolytic compe-
tence of AFG3L2, including its autocatalytic processing.48 By
contrast, the SCA28 mutations, which affect the proteolytic
domain, do not significantly alter the dislocase activity.25,29
From this standpoint, the second AFG3L2mutation identified
in Family 6 (p.Q620K, located in the proteolytic domain)
resembles a mild SCA28 mutation, which corresponds
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perfectly to the mild late onset ataxia phenotype observed in
the heterozygous p.Q620K subject from this study (F6 I-1).
However, although the p.Q620K clearly impairs yeast respira-
tion, it does not significantly affect substrate processing. Fur-
thermore, it is rescued by paraplegin coexpression, as observed
in most SCA28 mutations25,29 (S. Magri and F. Taroni,
unpublished observation) but not in DOA mutations.25 Con-
sistently, the Family 6 member carrying this variant alone
(F6 I-1) did not exhibit any ophthalmological symptoms, but
only a very mild late onset ataxia that he was not even subjec-
tively aware of at age 64 years. According to the structural
model,47 all the DOA mutations identified in our patients’
cohort cluster in regions of the ATPase domain linked to 3 dis-
tinct functions: (1) ATP binding (Walker A and arginine fin-
ger: p.L346F, p.T355M, p.A462V, and
p.R465K), (2) ATP hydrolysis (Walker B and α5: p.D407G
and p.T430I), and (3) substrate interaction (p.F377S). Over-
all, our results conclusively demonstrate that AFG3L2 muta-
tions with clearly distinct biochemical impact account for the
different patient phenotypes (ie, SCA28 vs DOA). Further evi-
dence indicating that variants associated with SCA28 behave
differently from those reported in the present article comes
from a recently described knock-in SCA28mousemodel carry-
ing a patient-derived missense mutation (p.M665R) in the
AFG3L2 proteolytic domain, which showsmitochondrial frag-
mentation and increased OPA1 processing from long to short
isoforms in cerebellum and brain, but not in optic nerves.49
Interestingly, 3 families (F6, F11, and F12) harbored
AFG3L2 biallelic mutations. In Families 11 and 12, the
2 sporadic patients were compound heterozygous for a
missense change located outside the ATPase domain
(p.K306E or p.Y605C) and a frameshift mutation
(p.S634* or p.E793*). Because the heterozygous parents
were clinically unaffected, these 4 variants likely represent
hypomorphic/recessive mutations. By contrast, in domi-
nant Family 6, the 2 subjects (I-2 and II-2) harboring the
recurrent p.A462V variant alone present with optic atro-
phy, whereas the patient (II-1) compound heterozygous
for pA462V and p.Q620K exhibits a severe childhood
onset optic atrophy “plus” phenotype. The only very mild
late onset clinical symptoms in the subject carrying
p.Q620K alone (F6 I-1) indicates that this variant may
act as a hypomorphic variant, with a strong effect as a
phenotypic modifier, a notion that resembles findings
from OPA1, where also hypomorphic variants act as
intralocus phenotypic modifiers causing severe childhood
onset multisystemic optic atrophy phenotypes.17,50
In conclusion, our study expands the landscape of
genetic causes leading to optic atrophy, elucidates the underly-
ing molecular mechanisms, and describes the general para-
digm of specific vulnerability of retinal ganglion cells to
mitochondrial dysfunction, with common clinical features
undistinguishable from those known for the most common
DOA caused by OPA1 mutations. Furthermore, our results
provide conclusive evidence that OPA1 is the key player in
the pathogenesis of optic nerve degeneration, and its
processing is a crucial step that involves the entire set of mito-
chondrial AAA proteases, either directly (i-AAA: YME1L) or
indirectly (m-AAA: AFG3L2 and SPG7). Finally, this study
illustrates the broad spectrum of clinical manifestations and
genetic mechanisms (dominant, dominant de novo, recessive)
associated with AFG3L2 mutations and indicates that this
gene shall be included in the diagnostic algorithm for both
pure and syndromic optic neuropathies.
Acknowledgment
The “Cell Line and DNA Bank of Genetic Movement Disor-
ders and Mitochondrial Diseases” of the Telethon Network of
Genetic Biobanks (grant GTB12001J) and the EurobiobanK
Network supplied biological specimens. This work was
supported by the Telethon Foundation (grant GGP15041 to
D.G.), the E-Rare project GENOMIT (to C.L.), the
Pierfranco and Luisa Mariani Foundation, the Italian
Ministry of Health (grants GR-2016-02361449 to L.C.,
RF-2011-02351165 and RF-2018-12367768 to F.Tar.,
and GR-2016-02363337 to S.M., and “Ricerca Corrente”
funding to V.C.), the Horizon 2020 research and innova-
tion program (grant 779257 “Solve-RD” to R.S. and M.S.),
and the NIH (grant 5R01NS072248 to R.S.).
Author Contributions
L.C., S.M., D.G., V.C., and F.Tar. conceived and designed
the study; L.C., S.M., A.L., V.D.D., F.Tag., F.B., A.N.,
C.L.M., M.Car., M.L.V., E.L., S.B., L.S., R.S., P.B.,
M.L.C., A.M., M.Cap., A.A., D.P., G.C., L.M., M.Z., L.P.,
C.L., S.B.M., M.F., M.S., and D.G., contributed to the
acquisition and analysis of data; L.C., S.M., D.G., V.C., and
F.Tar. drafted the text and prepared the figures.
Potential Conflicts of Interest
Nothing to report.
References
1. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as
a cause of optic neuropathies. Prog Retin Eye Res 2004;23:53–89.
2. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic
neuropathies—disease mechanisms and therapeutic strategies. Prog
Retin Eye Res 2011;30:81–114.
3. Alexander C, Votruba M, Pesch UE, et al. OPA1, encoding a
dynamin-related GTPase, is mutated in autosomal dominant optic
atrophy linked to chromosome 3q28. Nat Genet 2000;26:211–215.
13
Caporali et al: AFG3L2 and Optic Neuropathy
4. Delettre C, Lenaers G, Griffoin JM, et al. Nuclear gene OPA1,
encoding a mitochondrial dynamin-related protein, is mutated in
dominant optic atrophy. Nat Genet 2000;26:207–210.
5. Lenaers G, Hamel C, Delettre C, et al. Dominant optic atrophy.
Orphanet J Rare Dis 2012;7:46.
6. Yu-Wai-Man P, Chinnery PF. Dominant optic atrophy: novel OPA1
mutations and revised prevalence estimates. Ophthalmology 2013;
120:1712–1712.e1.
7. Anand R, Wai T, Baker MJ, et al. The i-AAA protease YME1L and
OMA1 cleave OPA1 to balance mitochondrial fusion and fission.
J Cell Biol 2014;204:919–929.
8. MacVicar T, Langer T. OPA1 processing in cell death and disease—
the long and short of it. J Cell Sci 2016;129:2297–2306.
9. Mishra P, Carelli V, Manfredi G, Chan DC. Proteolytic cleavage of
Opa1 stimulates mitochondrial inner membrane fusion and couples
fusion to oxidative phosphorylation. Cell Metab 2014;19:630–641.
10. Cogliati S, Frezza C, Soriano ME, et al. Mitochondrial cristae shape
determines respiratory chain supercomplexes assembly and respira-
tory efficiency. Cell 2013;155:160–171.
11. Zanna C, Ghelli A, Porcelli AM, et al. OPA1 mutations associated
with dominant optic atrophy impair oxidative phosphorylation and
mitochondrial fusion. Brain 2008;131:352–367.
12. Lodi R, Tonon C, Valentino ML, et al. Defective mitochondrial aden-
osine triphosphate production in skeletal muscle from patients with
dominant optic atrophy due to OPA1 mutations. Arch Neurol 2011;
68:67–73.
13. Ferré M, Caignard A, Milea D, et al. Improved locus-specific data-
base for OPA1 mutations allows inclusion of advanced clinical data.
Hum Mutat 2015;36:20–25.
14. Amati-Bonneau P, Valentino ML, Reynier P, et al. OPA1 mutations
induce mitochondrial DNA instability and optic atrophy “plus” phe-
notypes. Brain 2008;131:338–351.
15. Yu-Wai-Man P, Griffiths PG, Gorman GS, et al. Multi-system neuro-
logical disease is common in patients with OPA1 mutations. Brain
2010;133:771–786.
16. Carelli V, Musumeci O, Caporali L, et al. Syndromic parkinsonism
and dementia associated with OPA1 missense mutations. Ann Neu-
rol 2015;78:21–38.
17. Bonifert T, Karle KN, Tonagel F, et al. Pure and syndromic optic atro-
phy explained by deep intronic OPA1 mutations and an intralocus
modifier. Brain 2014;137:2164–2177.
18. Nasca A, Rizza T, Doimo M, et al. Not only dominant, not only optic
atrophy: expanding the clinical spectrum associated with OPA1
mutations. Orphanet J Rare Dis 2017;12:89.
19. Reynier P, Amati-Bonneau P, Verny C, et al. OPA3 gene mutations
responsible for autosomal dominant optic atrophy and cataract.
J Med Genet 2004;41:e110.
20. Grau T, Burbulla LF, Engl G, et al. A novel heterozygous OPA3 muta-
tion located in the mitochondrial target sequence results in altered
steady-state levels and fragmented mitochondrial network. J Med
Genet 2013;50:848–858.
21. Rendtorff ND, Lodahl M, Boulahbel H, et al. Identification of p.
A684V missense mutation in the WFS1 gene as a frequent cause of
autosomal dominant optic atrophy and hearing impairment.
Am J Med Genet A 2011;155A:1298–1313.
22. Gerber S, Charif M, Chevrollier A, et al. Mutations in DNM1L, as in
OPA1, result in dominant optic atrophy despite opposite effects on
mitochondrial fusion and fission. Brain 2017;140:2586–2596.
23. Charif M, Roubertie A, Salime S, et al. A novel mutation of AFG3L2
might cause dominant optic atrophy in patients with mild intellectual
disability. Front Genet 2015;6:311.
24. Colavito D, Maritan V, Suppiej A, et al. Non-syndromic isolated dom-
inant optic atrophy caused by the p.R468C mutation in the AFG3
like matrix AAA peptidase subunit 2 gene. Biomed Rep 2017;7:
451–454.
25. Magri S, Fracasso V, Plumari M, et al. Concurrent AFG3L2 and SPG7
mutations associated with syndromic parkinsonism and optic atrophy
with aberrant OPA1 processing and mitochondrial network fragmen-
tation. Hum Mutat 2018;39:2060–2071.
26. Esser K, Tursun B, Ingenhoven M, et al. A novel two-step mechanism
for removal of a mitochondrial signal sequence involves the mAAA
complex and the putative rhomboid protease Pcp1. J Mol Biol 2002;
323:835–843.
27. Nolden M, Ehses S, Koppen M, et al. The m-AAA protease defective
in hereditary spastic paraplegia controls ribosome assembly in mito-
chondria. Cell 2005;123:277–289.
28. Koppen M, Langer T. Protein degradation within mitochondria: ver-
satile activities of AAA proteases and other peptidases. Crit Rev Bio-
chem Mol Biol 2007;42:221–242.
29. Di Bella D, Lazzaro F, Brusco A, et al. Mutations in the mitochondrial
protease gene AFG3L2 cause dominant hereditary ataxia SCA28.
Nat Genet 2010;42:313–321.
30. Pierson TM, Adams D, Bonn F, et al. Whole-exome sequencing iden-
tifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy
syndrome linked to mitochondrial m-AAA proteases. PLoS Genet
2011;7:e1002325.
31. Del Dotto V, Fogazza M, Musiani F, et al. Deciphering OPA1 muta-
tions pathogenicity by combined analysis of human, mouse and
yeast cell models. Biochim Biophys Acta Mol Basis Dis 2018;1864:
3496–3514.
32. Nasca A, Nardecchia F, Commone A, et al. Clinical and biochemical
features in a patient with mitochondrial fission factor gene alteration.
Front Genet 2018;9:625 Available at: https://www.frontiersin.org/
articles/10.3389/fgene.2018.00625/full. Accessed September
20, 2019.
33. Invernizzi F, Ardissone A, Lamantea E, et al. Cavitating leu-
koencephalopathy with multiple mitochondrial dysfunction syndrome
and NFU1 mutations. Front Genet 2014;5:412.
34. Tatsuta T, Augustin S, Nolden M, et al. M-AAA protease-driven
membrane dislocation allows intramembrane cleavage by rhomboid
in mitochondria. EMBO J 2007;26:325–335.
35. Bonn F, Tatsuta T, Petrungaro C, et al. Presequence-dependent fold-
ing ensures MrpL32 processing by the m-AAA protease in mitochon-
dria. EMBO J 2011;30:2545–2556.
36. Song Z, Chen H, Fiket M, et al. OPA1 processing controls mitochon-
drial fusion and is regulated by mRNA splicing, membrane potential,
and Yme1L. J Cell Biol 2007;178:749–755.
37. Klebe S, Depienne C, Gerber S, et al. Spastic paraplegia gene 7 in
patients with spasticity and/or optic neuropathy. Brain 2012;135:
2980–2993.
38. Hartmann B, Wai T, Hu H, et al. Homozygous YME1L1 mutation cau-
ses mitochondriopathy with optic atrophy and mitochondrial network
fragmentation. Elife 2016;5:e16078.
39. Patron M, Sprenger H-G, Langer T. m-AAA proteases, mitochondrial
calcium homeostasis and neurodegeneration. Cell Res 2018;28:
296–306.
40. Richter U, Lahtinen T, Marttinen P, et al. Quality control of mitochon-
drial protein synthesis is required for membrane integrity and cell fit-
ness. J Cell Biol 2015;211:373–389.
41. Almajan ER, Richter R, Paeger L, et al. AFG3L2 supports mitochon-
drial protein synthesis and Purkinje cell survival. J Clin Invest 2012;
122:4048–4058.
42. Maltecca F, De Stefani D, Cassina L, et al. Respiratory dysfunction by
AFG3L2 deficiency causes decreased mitochondrial calcium uptake
via organellar network fragmentation. Hum Mol Genet 2012;21:
3858–3870.
14 Volume 00, No. 0
ANNALS of Neurology
43. Ferreirinha F, Quattrini A, Pirozzi M, et al. Axonal degeneration in
paraplegin-deficient mice is associated with abnormal mitochondria
and impairment of axonal transport. J Clin Invest 2004;113:231–242.
44. Pfeffer G, Gorman GS, Griffin H, et al. Mutations in the SPG7 gene
cause chronic progressive external ophthalmoplegia through disor-
dered mitochondrial DNA maintenance. Brain 2014;137:1323–1336.
45. Yu-Wai-Man P, Votruba M, Burté F, et al. A neurodegenerative per-
spective on mitochondrial optic neuropathies. Acta Neuropathol
2016;132:789–806.
46. Burté F, Carelli V, Chinnery PF, Yu-Wai-Man P. Disturbed mitochon-
drial dynamics and neurodegenerative disorders. Nat Rev Neurol
2015;11:11–24.
47. Puchades C, Ding B, Song A, et al. Unique structural features of the
mitochondrial AAA+ protease AFG3L2 reveal the molecular basis for
activity in health and disease. Mol Cell 2019;75:1073–1085.e6.
48. Koppen M, Bonn F, Ehses S, Langer T. Autocatalytic processing of
m-AAA protease subunits in mitochondria. Mol Biol Cell 2009;20:
4216–4224.
49. Mancini C, Hoxha E, Iommarini L, et al. Mice harbouring a SCA28
patient mutation in AFG3L2 develop late-onset ataxia associated
with enhanced mitochondrial proteotoxicity. Neurobiol Dis 2019;
124:14–28.
50. Carelli V, Sabatelli M, Carrozzo R, et al. “Behr syndrome” with OPA1
compound heterozygote mutations. Brain 2015;138:e321.
15
Caporali et al: AFG3L2 and Optic Neuropathy
